Long-Term Optimism,<br />Short-Term Caution<br />By Rev Shark<br />RealMoney.com Contributor<br />12/13/2007 8:08 AM EST <br /><br /><br />The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails. <br />-- William Arthur Ward<br /><br />The market's failure to embrace the Fed's scheme to increase liquidity in the banking system casts a gloomy pall as we enter the last few weeks of the year. If the mighty Fed, with all its tools and power, can't contain fears over subprime debt problems and shore up investor confidence, what's going to reassure this market? <br /><br />There is no shortage of armchair pundits who are willing to offer advice to Ben Bernanke and his staff, but what you really have to wonder is whether the economic cycle is destined to play out like it always does, no matter how much we flail about for solutions. Trying to stop an economic contraction as real estate loses trillions in values and billions in debt is written off is like trying to prevent the seasons from changing. The economic system is going to purge itself of its problems one way or another, and not even all the central banks in the world can stop it. <br /><br />That sounds rather depressing, but the key is how you look at it. In the long run, the cycle will turn up again like it always does, and that should keep us optimistic. The economic cycle will create opportunities if we are patient and aren't blinded by the short-term gloom and despair. <br /><br />In the shorter term, we need to adjust to a more difficult environment. That means staying vigilant and protecting capital. <br /><br />There are going to be plenty of market pundits anxious to tell us how terrible things are going to get before they get better. We are going to hear predictions that we will undergo the worst economic crisis we have ever seen. That's possible, but it seldom works that way. Some people glory in that sort of pessimism, but for most people, it drains them of motivation and makes them forget about the opportunities that will eventually arise. <br /><br />The healthiest approach to the market for most investors is to be a long-term optimist while being short-term vigilant. As long as you are confident that things will eventually get better -- as I am -- you will have the motivation and drive to navigate the angry market seas we presently face. <br /><br />And angry they are at the moment. The mood is sour, the technical conditions are poor and few positive catalysts exist. Market players are lacking confidence and that tends to feed on itself. <br /><br />We have a poor open shaping up as overseas markets rejected the Fed liquidity move and increased their worries over the subprime issues. The market is flailing around as it looks for some real solution to the bad-debt mess, and it isn't finding one. Stay vigilant and defensive and let this play out. <br />--------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: MATK +13.2%, ADCT +8.7% (also upgraded to Buy at Merriman), JOSB +6.6%, GXDX +6.2% (also initiated with Outperform at Cowen), KMGB +3.6%, HAYN +3.3%, CIEN +2.6%, MDZ +1.1%, LII +1.1%, HON +1.0%... M&A news: MGI +27.5% (to be acquired by EEFT for $20/share)... Other news: RIGL +75.0% (demonstrates significant improvement in rheumatoid arthritis in Phase 2 clinical study), SVNT +45.2% (meets pre-specified primary efficacy endpoint in two replicate Phase 3 studies ), DEPO +21.2% (says Court grants motion for Summary Judgement of patent infringement against IVAX), DOW +7.8% (DOW and Petrochemical Industries announce plans to form a 50/50 joint venture in global petrochemicals co) PSPT +7.5% (Board rejects IPVG and AO Capital Partners unsolicited proposal of $15/share), VNDA +4.0% (presents Phase 3 iloperidone efficacy data), XMSR +3.7% (members of US House Antitrust Panel express concern over merger - Reuters), UMBF +3.2% (will replace EDO in S&P SmallCap 600), RATE +2.4% (initiated with Neutral at BofA), CPSL +2.0% (announces that it has new independent registered public accounting firm). Analyst upgrades: ESLR +4.1% (initiated with Buy at UBS), JRCC +3.9% (initiated with Buy at UBS), RATE +2.4% (initiated with Neutral and $55 tgt at BofA), CYNO +2.2% (upgraded to Buy at Citigroup), GA +2.0% (initiated with Buy at UBS).<br /><br />Allapoole avanevad:<br /><br />In reaction to weak earnings/guidance: ASYS -17.8% SCSS -15.7% (Discloses in its 8-K that sales profits will fall short of previous guidance), COST -6.3%, VITL -6.2%, CKR -4.7%, LEH -2.1%, CPII -1.3%, NSPH -1.1%... Other news: NBIX -46.3% (receives approvable letter for indiplon capsules with additional safety and efficacy data required by FDA), BIIB -27.5% (completes review of strategic alternatives; did not receive any definitive offers), ADPI -23.3% (provides update on lawsuit -- jury found PDHC or ADPI liable for breach of the service agreement and awarded compensatory damages of $9.4 mln; this follows yesterday's 27% sell-off in the stock), WSTL -8.5% (receives notice of SEC investigation), SCA -8.3% (Fitch reviewing its AAA ratings), ELN -6.2% (in response to BIIB announcement, co reaffirms commitment to Tysabri), ACH -5.3% (still checking), LIHR -5.1% (cuts production forecast by 7% to 700k oz - DJ), POT -4.3% (files for a $2 bln debt securities shelf offering), BIDZ -4.3% (presented at Wedbush conference after the close, issues guidance), QCOM -2.4% (judge issues ruling saying NOK does not infringe QCOM in patent infringement complaint, also downgraded to Neutral at Merrill), MT -1.3% (to increase stake in China Oriental), AGU -1.0% (prices secondary offering at $58)... Analyst downgrades: RIO -3.6% (hearing downgraded to Neutral at tier-1 firm), WM -3.1% (downgraded to Sell at BofA), COF -2.6% (downgraded to Hold at Jefferies), RHT -2.2% (downgraded to Sell at BofA), PMCS -1.4% (initiated with Sell at BofA), CME -1.0% (hearing removed from Conviction Buy list at tier-1 firm).